Skip to main content
SpringerLink
Log in

Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose

  • Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Glucose intolerance and diabetes mellitus are both prevalent in patients with chronic liver diseases. We examined the efficacy and systemic safety of therapy with an alpha-glucosidase inhibitor, acarbose, in diabetes mellitus associated with chronic liver diseases. Twenty patients with chronic hepatitis or liver cirrhosis and overt diabetes mellitus received acarbose (taken orally) for 8 weeks. The initial dosage of acarbose was 50mg three times daily, taken before meals; this was increased to 100mg three times daily after 2 weeks. The mean fasting plasma glucose level was 173.7±18.6mg/dl (mean±SE) at entry, and was significantly decreased to 132.9±7.5mg/dl (P<0.05) after 8 weeks of acarbose treatment. The improved glycemic control was reflected by a significant decrease in glycosylated hemoglobin (HbA1c) from 7.2±0.3% at entry to 6.3±0.2% (P<0.05) after 8 weeks. Serum levels of both aspartate and alanine aminotransferases fluctuated during acarbose treatment, probably due to the natural course of chronic liver diseases, but the mean values had decreased after 8 weeks of treatment. Plasma ammonia levels increased, from 61.3±10.7μg/dl to 71.1±9.6μg/dl after 8 weeks of acarbose treatment but the increase was not significant. Clinically significant elevation of plasma ammonia concentration was seen in 2 cirrhotic patients (121 and 124μg/dl); this was asymptomatic and gradually returned to the normal range despite continuous acarbose treatment in one patient, and was reversed after the withdrawal of acarbose with the concomitant administration of lactulose in the other patient. No other blood tests results, including albumin, cholinesterase, and prothrombin time, or lipid profile and nutritional status, in terms of rapid turnover proteins, prealbumin, retinol binding protein, and transferrin, were altered throughout the study period. These results indicate that diabetes mellitus associated with chronic liver diseases may be safely and effectively treated with acarbose. However, clinicians must be aware of the possibility of hyperammonemia when they prescribe acarbose for patients with diabetes mellitus and advanced liver cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clissold SP, Edwards C. Acarbose, preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988;35:214–243.

    Article  PubMed  CAS  Google Scholar 

  2. Puls W, Keup U, Krause HP, et al. Glucosidase inhibition: A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften 1977;64:536–537.

    Article  PubMed  CAS  Google Scholar 

  3. Puls W, Krause HP. Delay of carbohydrate absorption by inhibitors of intestinal alpha-glucosidases. Adv Exp Med Biol 1979; 119:341–346.

    PubMed  CAS  Google Scholar 

  4. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732–737.

    Article  PubMed  CAS  Google Scholar 

  5. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994;17:561–566.

    Article  PubMed  CAS  Google Scholar 

  6. Leonhardt W, Hanefeld M, Fischer S, et al. Efficacy of Éϕ-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidemia. Eur J Clin Invest 1994;24(Suple 3):45–49.

    PubMed  Google Scholar 

  7. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver diseases. Lancet 1967;II:1051–1055.

    Article  Google Scholar 

  8. Creutsfeld W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. In: Popper H, Schaffner F (eds) Progress in liver diseases, vol. III. New York: Grune and Stratton, 1970:371–407.

    Google Scholar 

  9. Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: A review with some perspectives for the future. Diabetes Metab Rev 1989;5:691–709.

    PubMed  CAS  Google Scholar 

  10. Del Vecchio Blanco C, Gentile S, Marmo R, et al. Alterations of glucose metabolism in chronic liver diseases. Diabetes Res Clin Pract 1990;8:29–36.

    Article  Google Scholar 

  11. Gentile S, Loguercio C, Marmo R, et al. Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Res Clin Pract 1993;22:37–44.

    Article  PubMed  CAS  Google Scholar 

  12. Kingston ME, Ali MA, Atiyeh M, et al. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 1984;87: 688–694.

    PubMed  CAS  Google Scholar 

  13. Samols E, Ryder J. Studies on tissue uptake of insulin in man using a differential immunoassay for endogenous and exogenous insulin. J Clin Invest 1961;40:2092–2102.

    Article  PubMed  CAS  Google Scholar 

  14. Petrides AS, Groop LC, Riely CA, et al. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J Clin Invest 1991;88:561–570.

    Article  PubMed  CAS  Google Scholar 

  15. Müller MJ, Willmann O, Rieger A, et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology 1992;102:2033–2041.

    PubMed  Google Scholar 

  16. Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrohsis. Hepatology 1994;20:119–125.

    PubMed  CAS  Google Scholar 

  17. Balfour JA, McTavish D, Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025–1054.

    Article  PubMed  CAS  Google Scholar 

  18. Coniff RF, Shapiro JA, Timothy B, et al. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154:2442–2448.

    Article  PubMed  CAS  Google Scholar 

  19. Pugh RNH, Murray-Layon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–649.

    Article  PubMed  CAS  Google Scholar 

  20. Chuas KS, Tan IK. Plasma glucose measurement with the Yellow Springs Glucose Analyzer. Clin Chem 1978;24:470–475.

    Google Scholar 

  21. Cole RA, Soeldner JS, Dunn PJ, et al. A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography. Metabolism 1978;27:289–301.

    Article  PubMed  CAS  Google Scholar 

  22. Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;2:470–475.

    Google Scholar 

  23. The Diabetes Control and Complications Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.

    Article  Google Scholar 

  24. Spengler M, Cagatay M. The use of acarbose in the primary-care setting: Evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study. Clin Invest Med 1995;18:325–331.

    PubMed  CAS  Google Scholar 

  25. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995;18:817–824.

    Article  PubMed  CAS  Google Scholar 

  26. Andrade RJ, Lucena MI, Rodriguez-Mendizábal M. Hepatic injury caused by acarbose. Ann Intern Med 1996;124:931.

    PubMed  CAS  Google Scholar 

  27. Zillikens MC, Swart GR, Van den Berg JWO, et al. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther 1989;3:453–459.

    Article  PubMed  CAS  Google Scholar 

  28. Müting D. Acarbose bei der Behandlung von Diabetikern mit gleichzeitiger Leberzirrhose. Therapiewoche 1984;34:2566–2572.

    Google Scholar 

  29. Goto Y, Nakagawa S, Goto Y, et al. A double-blind study on the efficacy of BAY g 5421 (acarbose) in non-insulin dependent diabetes mellitus (NIDDM) (in Japanese). Igaku no Ayumi 1989; 149:591–618.

    Google Scholar 

  30. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928–935.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Department of Internal Medicine, University of Occupational and Environmental Health Japan, School of Medicine, 1-1 Iseigaoka, Yahatanishi-ku, 807, Kitakyushu, Japan

    Yasuyuki Kihara, Yoshimitsu Ogami, Akinari Tabaru, Hideaki Unoki & Makoto Otsuki

Authors
  1. Yasuyuki Kihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshimitsu Ogami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akinari Tabaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideaki Unoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Otsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kihara, Y., Ogami, Y., Tabaru, A. et al. Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose. J Gastroenterol 32, 777–782 (1997). https://doi.org/10.1007/BF02936954

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02936954

Key words

Search

Navigation